Drug Trial News

RSS

HCV protease inhibitor telaprevir improves response, halves treatment time for hepatitis C patients

For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.

5 Jun 2009

Tuberculosis booster vaccine trials to begin next month In South Africa

A new two-year trial to test a tuberculosis vaccine aimed at boosting the efficacy of the BCG vaccine is scheduled to begin soon in South Africa, IRIN reports (IRIN, 6/4).

5 Jun 2009

Experimental drug five times more effective against MDR-TB than conventional therapy

A Johnson & Johnson-run study found that its experimental drug TMC207 could make conventional tuberculosis treatment five times more effective against multi-drug resistant TB (MDR-TB) because it cleared traces of the TB bacteria in the sputum of 48 percent of study volunteers after eight weeks, Reuters reports (Emery, Reuters, 6/3). The results were published on Wednesday in the New England Journal of Medicine.

4 Jun 2009

Trial results show better survival for gallbladder and bile duct cancer

Combining two chemotherapy drugs for advanced gallbladder and bile duct cancer improves survival by a third, according to results from a Cancer Research UK funded trial presented today at the American Society of Clinical Oncology (ASCO) conference.

2 Jun 2009

Study to evaluate ‘Active Hexose Correlated Compound’ and the swine flu virus

A study evaluating the effect of AHCC (Active Hexose Correlated Compound) on supporting the immune system in response to the swine flu virus will be conducted at the Southern China Agricultural University, one of the few research centers in China that have been approved to conduct studies on highly infectious diseases such as the swine flu. This controlled study will examine the effects of AHCC when supplemented to a group of mice infected with the virus.

1 Jun 2009

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

1 Jun 2009

Citalopram no more effective than a placebo for children with autism spectrum disorders

Citalopram, a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to researchers funded by the National Institute of Mental Health (NIMH) and other NIH institutes. The study was published in the June 2009 issue of Archives of General Psychiatry.

1 Jun 2009

Bayer announces new data on novel anti-cancer compound

Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

1 Jun 2009

Blood pressure drug reverses liver damage

British scientists have discovered that blood-pressure drugs can reverse the effects of early-stage liver failure in some patients.

1 Jun 2009

Iressa (gefinitib) chemotherapy combination proves safe for head and neck cancer patients

Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI).

31 May 2009

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.

31 May 2009

Blood-pressure medicine shown to reverse the effects of early-stage liver failure

Newcastle University researchers analysed a small clinical trial of losartan, a drug normally prescribed for hypertension, on 14 patients in Spain, who had Hepatitis C.

31 May 2009

Catalyst Pharmaceutical Partners announces top-line results of CPP-109 phase II trial for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. has announced top-line results from its U.S. Phase II clinical trial to treat cocaine addiction.

31 May 2009

Abraxane prolongs survival in metastatic breast cancer

Research from the Northwestern University Feinberg School of Medicine has found that a less toxic, solvent-free chemotherapy drug more effectively prevents the progression of metastatic breast cancer and has fewer side effects than a commonly used solvent-based drug.

26 May 2009

Diabetes drug pioglitazone shows potential against multiple sclerosis

A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago College of Medicine report in a study currently available online in the Journal of Neuroimmunology.

26 May 2009

Bioniche updates on phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc. has provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guérin (BCG).

25 May 2009

Zyflamend, herb-based therapeutic shows promise for high risk of prostate cancer

Results of a phase I clinical trial of a novel herb-based therapeutic called Zyflamend have demonstrated that the therapy is associated with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer.

22 May 2009

Aspirin and an anti-clotting drug ‘combo’ reduces risk of dialysis access failure

For the first time, a combination of aspirin and the anti-platelet drug dipyridamole has been shown to significantly reduce blockages and extend the useful life of new artery-vein access grafts used for hemodialysis, according to a study by the Dialysis Access Consortium (DAC).

21 May 2009

ChemGenex’s Omacetaxine to be showcased in three oral oresentations at EHA

ChemGenex Pharmaceuticals Limited announced today that new data from two clinical studies and one pre-clinical study with omacetaxine will be presented at oral sessions during the forthcoming 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.

21 May 2009

Trial tests potential new angina treatment

As part of a multi-center clinical trial, UC San Diego Medical Center is evaluating the safety and effectiveness of a potential new way to treat angina - by injecting a protein that stimulates the growth of new oxygen-rich blood vessels directly into the heart. Angina is a debilitating form of chest pain caused by coronary artery disease that affects more than nine million Americans.

20 May 2009

Drug Trial News

HCV protease inhibitor telaprevir improves response, halves treatment time for hepatitis C patients

Tuberculosis booster vaccine trials to begin next month In South Africa

Experimental drug five times more effective against MDR-TB than conventional therapy

Trial results show better survival for gallbladder and bile duct cancer

Study to evaluate ‘Active Hexose Correlated Compound’ and the swine flu virus

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

Citalopram no more effective than a placebo for children with autism spectrum disorders

Bayer announces new data on novel anti-cancer compound

Blood pressure drug reverses liver damage

Iressa (gefinitib) chemotherapy combination proves safe for head and neck cancer patients

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

Blood-pressure medicine shown to reverse the effects of early-stage liver failure

Catalyst Pharmaceutical Partners announces top-line results of CPP-109 phase II trial for cocaine addiction

Abraxane prolongs survival in metastatic breast cancer

Diabetes drug pioglitazone shows potential against multiple sclerosis

Bioniche updates on phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer

Zyflamend, herb-based therapeutic shows promise for high risk of prostate cancer

Aspirin and an anti-clotting drug ‘combo’ reduces risk of dialysis access failure

ChemGenex’s Omacetaxine to be showcased in three oral oresentations at EHA

Trial tests potential new angina treatment

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News